BofA Securities Upgrades Inovio Pharmaceuticals (INO) to Neutral
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $10.16 -2.03%
Rating Summary:
8 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
8 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
BofA Securities analyst Geoff Meacham upgraded Inovio Pharmaceuticals (NASDAQ: INO) from Underperform to Neutral with a price target of $10.00 (from $8.00).
For an analyst ratings summary and ratings history on Inovio Pharmaceuticals click here. For more ratings news on Inovio Pharmaceuticals click here.
Shares of Inovio Pharmaceuticals closed at $4.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
- Hindustan Unilever Ltd (HUVR:IN) PT Lowered to INR2,560 at JPMorgan
- Trelleborg AB (TRELB:SS) (TBABF) PT Raised to SEK376 at Barclays
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
